生物活性 | |||
---|---|---|---|
描述 | Trimebutine maleate is an orally administered anti-tumor agent. It has the ability to selectively inhibit the stemness and proliferation of ovarian cancer stem cells (CSCs). Additionally, Trimebutine maleate alleviates colonic muscle hypercontractility, regulates gastrointestinal motility, and promotes apoptosis, making it a valuable candidate for research in glioma/glioblastoma and irritable bowel syndrome[1].[2].[3].[4].[5].[6]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01507922 | Irritable Bowel Syndrome | Phase 4 | Completed | - | Korea, Republic of ... 展开 >> Korea University Ansan Hospital Ansan, Korea, Republic of Hallym University Sacred Heart Hospital Anyang, Korea, Republic of Kangwon National University Hospital Chuncheon, Korea, Republic of Gachon University Gil Hospital Incheon, Korea, Republic of Inje University Seoul Paik Hospital Seoul, Korea, Republic of Korea University Anam Hospital Seoul, Korea, Republic of Korea University Guro Hospital Seoul, Korea, Republic of 收起 << |
NCT02986685 | Refractory Reflux Esophagitis | Phase 4 | Unknown | November 2017 | China, Shaanxi ... 展开 >> Xijing Hosipital of Digestive Disease Recruiting Xi`an, Shaanxi, China, 710032 Contact: Yongquan Shi, professor 86-029-84771515 shiyquan@fmmu.edu.cn 收起 << |
NCT01984931 | Nausea Vomiti... 展开 >>ng 收起 << | Phase 3 | Unknown | December 2013 | Korea, Republic of ... 展开 >> Chungmu General Hopsital Recruiting Seoul, Yeongdeungpo-gu, Korea, Republic of, 150-034 Contact: Sang Hoon Lhee, MD, Phd +82 (2) 2068/4525 cmirb@naver.com Principal Investigator: Paolo Alan B Tabar, MD 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.99mL 0.40mL 0.20mL |
9.93mL 1.99mL 0.99mL |
19.86mL 3.97mL 1.99mL |